SureTrader
Home > Boards > US OTC > Medical - Drugs >

Intiva Biopharma Inc. (NTVA)

NTVA RSS Feed
Add NTVA Price Alert      Hide Sticky   Hide Intro
Moderator: FELLER, High_Profits, GOIN/Green
Search This Board: 
Last Post: 1/18/2018 3:51:17 PM - Followers: 43 - Board type: Free - Posts Today: 0

Intiva Biopharma Inc.

Stock Symbol = NTVA 



https://www.intivabiopharma.com/


 
INTIVA BioPharma Inc. is a potentially disruptive drug development company
focused on cannabinoid-based pharmaceutical solutions.

 
 
The Company is researching and developing drug and cannabinoid molecules
for various medical conditions and diseases.  
ArcView Market Research estimates that
America's pharmaceutical cannabis sector could reach over $23 billion by 2020. 
 
 

INTIVA’S DRUG DEVELOPMENT ACTIVITIES

INTIVA’s drug development strategy consists of:

1. The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations;

2. Conducting “freedom to operate” investigations on these conditions;

3. The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents;

4. Identifying the regulatory pathway with the U.S. Food and Drug Administration (FDA); and

5. Proceeding with clinical studies and clinical trials under FDA protocols for submission to obtain approval for the drug(s).

 

Because of the federal illegality of cannabis in the United States,
INTIVA is focusing its initial drug development using
 synthetic cannabinoids,
some of which are approved by the FDA for various medical conditions.

Synthetic cannabinoids generally simplify research development in the U.S.
However, INTIVA also intends to proceed with trials using plant-derived cannabinoids.
Because of the difficulty in proceeding with those trials in the United States,
the INTIVA will likely proceed with those trials in jurisdictions where the research is legal, such as Israel.

 

Jeffrey Friedland, Chief Executive Officer, and Director

Jeffrey Friedland is the Chief Executive Officer of the Company. He is also the Chief Executive Officer and Chairman of the Board of INTIVA Inc., https://www.intiva.us/  and has served in those positions since the inception of the Company in February 2014.  He also is a co-founder of the INTIVA Inc.

Mr. Friedland is a founder of Israel-based, Israel Plant Sciences Ltd., a company that is participating in Israel’s innovative agriculture and medicinal plant sectors and other agricultural related technologies, with a primary focus on cannabis.  Mr. Friedland is also a director of CannRx a US-based company with its principal operations in Israel that is researching the medical benefits of cannabis-based pharmaceuticals. 

In addition,  Jeff is on the Board of Advisors of OWC Pharmaceutical Research Corp.  http://www.owcpharma.com/  [symbol : OWCP]  an Israeli Medical Research company doing real Marajuana Medical Research and Clinical Trials in Israel.   Link to Clinical Trial ... 
http://tinyurl.com/ycgallvw

 

In his recently-published second book, "Marijuana: the World's Most Misunderstood Plant",
Mr. Friedland dives into the world of marijuana, discussing the history of the plant,
what we know and what we still hope to discover.   


View it on Amazon Books ... 
http://tinyurl.com/ybsttnwn

Since 1981, Mr. Friedland has provided investment banking, merchant banking, and corporate finance advisory services to hundreds of privately-held and listed companies worldwide.  These services have included obtaining venture capital and private equity capital, mergers and acquisitions, and assistance to companies regarding financing their growth and becoming stock market listed on stock exchanges worldwide.   Mr. Friedland has been the chief executive officer and a director of a NASDAQ-listed financial services company, a director, and chairman of the audit committee of a New York Stock Exchange-listed company, and chairman of a company listed on the EU-regulated market of the Frankfurt Stock Exchange.

 

He is an author, speaker and thought leader on emerging markets, the global economy, and the cannabis industry. He has been featured or quoted in numerous publications including the Wall Street Journal, Reuters, the New York Times, USA Today, the South China Morning Post, the Guam Daily Post, Bloomberg, the Forward, the Jewish Week, Quartz, the Jakarta Globe, Israel Daily Television, BreitBart,  NBC.com and Forbes.

 

Jeffrey Friedland's personal website for his link to his book, his articles and videos: www.jeffreyfriedland.com
 

____________________________________

Recent INVTIVA BIOPHARMA INC. SEC FILINGS
____________________________________

https://www.otcmarkets.com/stock/NTVA/filings


Shares O/S Approx 44 Million 

_________________________________________

Recent Company NEWS
_________________________________________

Intiva BioPharma Submits a Request to the FDA for a Pre-Investigational New Drug Meeting
for a Pharmaceutical Product for Use in the Acute Treatment During and Immediately Following Exposure to Nerve Agents


https://www.intivabiopharma.com/intiva-biopharma-news




_______________________________________________________________________

Corporate VIDEO with Dr. Joseph Morgan
_______________________________________________________________________

"The Use of Cannabinoids as a Preventative and Therapy
for Exposure to Organophosphates and Nerve Agents Such as Sarin Gas"


https://www.intivabiopharma.com/videos  


_______________________________________________________________________

Corporate VIDEO with CEO Jeffrey Friedland
_______________________________________________________________________

In this episode we continue our series on the emerging legal cannabis industry
and will be speaking with industry expert, investor and speaker,
Mr. Jeffrey Friedland who is also author of the book,
Marijuana: The World’s Most Misunderstood Plant


https://www.youtube.com/watch?v=fu-9B9bN_kM&feature=youtu.be



NEW Intiva Biopharma Investor Relations Announced 
Mark Lubchenco 
Phone =  (303) 431-4530 
Email = mlubchenco@intiva.us,  ir@intiva.us 

STOCK SYMBOL = NTVA
[changed Dec 28th, 2017 from KDRH / KDRHD] 


Like & Follow Intiva Biopharma on Social Media 

Facebook

https://www.facebook.com/IntivaBiopharma/

Twitter
https://twitter.com/IntivaBiopharma


 
SureTrader
NTVA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#1193  Sticky Note New CEO Interview [VIDEO] with Jeff Friedland - High_Profits 12/06/17 08:56:27 AM
#1322   Hopefully by February. FELLER 01/18/18 03:51:16 PM
#1321   Strong bid at 4.50 - just a matter Quintessence 01/18/18 01:46:50 PM
#1320   $NTVA - Intiva BioPharma [Video] Series with Jeff Friedland High_Profits 01/13/18 02:13:41 PM
#1319   New Video NTVA @IntivaBiopharma $OWCP @OWCPharma @jeff_friedland VIDEO Segment High_Profits 01/12/18 11:30:03 PM
#1318   It will come. Meanwhile I am trying Quintessence 01/12/18 05:20:40 PM
#1317   Doubt we hear anything from JF until after surfgreen 01/12/18 02:39:48 PM
#1316   I'm think'n we need a little news to BigBlackDog 01/12/18 02:04:38 PM
#1315   An Open Letter to Senator Cory Gardner High_Profits 01/12/18 07:55:36 AM
#1314   Nice I think some updates could be coming STOCKPICKER4LIFE 01/10/18 03:12:55 PM
#1313   I added today. Looks like it's moving Quintessence 01/10/18 02:49:58 PM
#1312   $NTVA CEO (VIDEO) High_Profits 01/08/18 10:03:02 PM
#1311   https://www.jeffreyfriedland.com/single-post/2018/01/08/Jeffrey-Friedland-Interv shanak10 01/08/18 07:56:52 PM
#1310   I agree on the FDA orphan drug designation Renegades17 01/07/18 12:55:11 PM
#1309   NTVA at half of GWPH's market value ($3.7B) FELLER 01/07/18 11:58:25 AM
#1308   As Jeff says, synthetic CBD is 100% legal Renegades17 01/07/18 10:10:07 AM
#1307   Watch "Marijuana Stocks of the Week: Jeff Sessions High_Profits 01/07/18 01:23:54 AM
#1306   https://www.youtube.com/watch?v=yeFkJtPwULw&feature=youtu.be shanak10 01/06/18 09:10:41 PM
#1305   $NTVA Cannabis Insider TV - Part 1 of High_Profits 01/06/18 07:46:46 PM
#1304   6.75 on the Ask. Would be nice Quintessence 01/05/18 12:51:03 PM
#1303   Just in case anyone feels like participating. GOIN/Green 01/05/18 12:15:46 PM
#1302   But my buy order didn't get filled. I Quintessence 01/05/18 08:53:32 AM
#1301   Note the comment on medical marijuana Renegades17 01/05/18 08:18:45 AM
#1300   And someone put in a silly market order apparently Renegades17 01/05/18 08:09:59 AM
#1299   Sessions... Sector wide sell off. GOIN/Green 01/04/18 08:38:09 PM
#1298   WTF is this onco 01/04/18 06:27:27 PM
#1297   Someone just got some cheap shares... Quintessence 01/04/18 03:58:19 PM
#1296   http://wallstconference.com/ GOIN/Green 01/03/18 08:01:49 PM
#1295   When is the conference? buxmaker 01/03/18 07:41:38 PM
#1294   Liking where this is going. Cant imagine where GOIN/Green 01/03/18 06:20:38 PM
#1293   Nice close at 6.00! New all-time high. Quintessence 01/03/18 04:03:06 PM
#1292   Yeah looks like the P.P buyers and insiders STOCKPICKER4LIFE 01/03/18 03:58:31 PM
#1291   6.00 on the Ask now. Not many shares available. Quintessence 01/03/18 11:35:41 AM
#1290   +15% and highest volume in a couple months. Quintessence 01/02/18 04:43:57 PM
#1289   Yeah looking good today.. Nice bids. STOCKPICKER4LIFE 01/02/18 03:07:56 PM
#1288   Bet they add NTVA in 2018 surfgreen 01/02/18 03:07:24 PM
#1287   New Marajuana ETF Just Launched MJX High_Profits 01/02/18 02:06:35 PM
#1286   Nice day so far. 4.80x5.50 showing on L2. Quintessence 01/02/18 09:47:44 AM
#1285   Yeah I think we could be hearing something STOCKPICKER4LIFE 01/01/18 06:20:21 PM
#1284   We could be hearing news on this in Farmer7 01/01/18 11:08:15 AM
#1283   I agree. And with Jeffrey Friedland - Quintessence 12/30/17 10:23:31 AM
#1282   There's very little free float Renegades17 12/30/17 10:05:05 AM
#1281   Not bad for a low-volume day. NTVA's Quintessence 12/29/17 04:11:37 PM
#1280   Slap the ask Quintessence Renegades17 12/29/17 02:55:01 PM
#1279   $NTVA$ January will be amazing. surfgreen 12/29/17 12:37:41 PM
#1278   Bid support at $3 now. Quintessence 12/29/17 12:04:26 PM
#1277   New 52-week high, $4.50 - still low volume, Quintessence 12/29/17 11:08:20 AM
#1276   Thanks... knew I had found it somewhere and GOIN/Green 12/28/17 12:47:47 PM
#1275   FDA announced this month fast track accelerated approval surfgreen 12/28/17 12:45:27 PM
#1274   In time all will be known. It's GOIN/Green 12/28/17 12:37:26 PM
#1273   Definitely not surprised to see such teeny-tiny volume. FELLER 12/28/17 12:18:36 PM
PostSubject